Pharmacokinetic and pharmacodynamic analysis of 5-aza-2’-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy

5-Aza-2′-deoxycytidine (5-AZA-CdR, decitabine), an epigenetic drug that inhibits DNA methylation, is currently used to treat myelodysplastic syndrome (MDS), and is under investigation for treating acute myeloid leukemia (AML) and other malignancies. 5-AZA-CdR can reactivate tumor suppressor genes si...

Descripción completa

Detalles Bibliográficos
Autores principales: Karahoca, Metin, Momparler, Richard L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570332/
https://www.ncbi.nlm.nih.gov/pubmed/23369223
http://dx.doi.org/10.1186/1868-7083-5-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570332/
https://www.ncbi.nlm.nih.gov/pubmed/23369223
http://dx.doi.org/10.1186/1868-7083-5-3

Ejemplares similares